Recommending flavanols and procyanidins for cardiovascular health: Current knowledge and future needs

Molecular Aspects of Medicine

Volumn 31, Issue 6, 2010, Pages 546-557

  Schroeter, Hagen ^a,d   Heiss, Christian ^b   Spencer, Jeremy P E ^c   Keen, Carl L ^d   Lupton, Joanne R ^e   Schmitz, Harold H ^a  

^a MARS INC   (United States)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF READING   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Cocoa; Diet; Epicatechin; Nutrition; Phytonutrient; Proanthocyanidins; Tea

Indexed keywords

FLAVONOL DERIVATIVE; PROCYANIDIN DERIVATIVE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG BLOOD LEVEL; FOOD COMPOSITION; FOOD INTAKE; FOOD SAFETY; HUMAN; LIFE EXPECTANCY; NONHUMAN; PHYTOCHEMISTRY; PRIMARY PREVENTION; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; THERAPY EFFECT;

CARDIOVASCULAR DISEASES; DIET; FLAVONOIDS; FORECASTING; HEALTH BEHAVIOR; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PLANNING GUIDELINES; HUMANS; PROANTHOCYANIDINS;

THEOBROMA CACAO;

EID: 78649631404     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2010.09.008     Document Type: Review

References (84)

1. Arts I.C., Hollman P.C. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005, 81(1 Suppl.):317S-325S.
2. Arts I.C., Jacobs D.R., Harnack L.J., Gross M., Folsom A.R. Dietary catechins in relation to coronary heart disease death among postmenopausal women. Epidemiology 2001, 12(6):668-675.
3. Auger C., Mullen W., Hara Y., Crozier A. Bioavailability of polyphenon E flavan-3-ols in humans with an ileostomy. J Nutr 2008, 138(8):1535S-1542S.
4. Baba S., Osakabe N., Natsume M., Muto Y., Takizawa T., Terao J. In vivo comparison of the bioavailability of (+)-catechin, (-)-epicatechin and their mixture in orally administered rats. J Nutr 2001, 131(11):2885-2891.
5. Baba S., Osakabe N., Yasuda A., Natsume M., Takizawa T., Nakamura T., Terao J. Bioavailability of (-)-epicatechin upon intake of chocolate and cocoa in human volunteers. Free Radic Res 2000, 33(5):635-641.
6. Balzer J., Rassaf T., Heiss C., Kleinbongard P., Lauer T., Merx M., Heussen N., Gross H.B., Keen C.L., Schroeter H., Kelm M. Sustained benefits in vascular function through flavanol-containing cocoa in medicated diabetic patients a double-masked, randomized, controlled trial. J Am Coll Cardiol 2008, 51(22):2141-2149.
7. Bayard V., Chamorro F., Motta J., Hollenberg N.K. Does flavanol intake influence mortality from nitric oxide-dependent processes? Ischemic heart disease, stroke, diabetes mellitus, and cancer in Panama. Int J Med Sci 2007, 4(1):53-58.
8. Bentley R., Trimen H. Medical Plants 1880, J. & A. Churchill, London.
9. Blatt D.H., Pryor W.A., Mata J.E., Rodriguez-Proteau R. Re-evaluation of the relative potency of synthetic and natural alpha-tocopherol: experimental and clinical observations. J Nutr Biochem 2004, 15(7):380-395.
10. Brocks D.R. Drug disposition in three dimensions: an update on stereoselectivity in pharmacokinetics. Biopharm Drug Dispos 2006, 27(8):387-406.
11. CFSAN, 2009. Guidance for industry: evidence-based review system for the scientific evaluation of health claims. Available from: http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodLabelingNutrition/ucm073332.htm.
12. Clifford A.J., de Moura F.F., Ho C.C., Chuang J.C., Follett J., Fadel J.G., Novotny J.A. A feasibility study quantifying in vivo human alpha-tocopherol metabolism. Am J Clin Nutr 2006, 84(6):1430-1441.
13. Colatsky T.J. Reassessing the validity of surrogate markers of drug efficacy in the treatment of coronary artery disease. Curr Opin Investig Drugs 2009, 10(3):239-244.
14. Corder R., Mullen W., Khan N.Q., Marks S.C., Wood E.G., Carrier M.J., Crozier A. Oenology: red wine procyanidins and vascular health. Nature 2006, 444(7119):566.
15. Desai M., Stockbridge N., Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J 2006, 8(1):E146-152.
16. Desch S., Kobler D., Schmidt J., Sonnabend M., Adams V., Sareban M., Eitel I., Bluher M., Schuler G., Thiele H. Low vs. higher-dose dark chocolate and blood pressure in cardiovascular high-risk patients. Am J Hypertens 2010, 23(6):694-700.
17. Dillinger T.L., Barriga P., Escarcega S., Jimenez M., Salazar Lowe D., Grivetti L.E. Food of the gods: cure for humanity? A cultural history of the medicinal and ritual use of chocolate. J Nutr 2000, 130(8S Suppl.):2057S-2072S.
18. Donovan J.L., Crespy V., Manach C., Morand C., Besson C., Scalbert A., Remesy C. Catechin is metabolized by both the small intestine and liver of rats. J Nutr 2001, 131(6):1753-1757.
19. Donovan J.L., Crespy V., Oliveira M., Cooper K.A., Gibson B.B., Williamson G. (+)-Catechin is more bioavailable than (-)-catechin: relevance to the bioavailability of catechin from cocoa. Free Radic Res 2006, 40(10):1029-1034.
20. Duffy S.J., Keaney J.F., Holbrook M., Gokce N., Swerdloff P.L., Frei B., Vita J.A. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001, 104(2):151-156.
21. Dymock W., Hooper D., Warden C.J.H. Pharmacographia Indica. A history of the principal drugs of vegetable origin, met with in British India 1890, British Library, London.
22. EFSA, 2006. Regulation on nutrition and health claims made on foods. Available from: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2006R1924:200803.
23. Erdman J.W., Balentine D., Arab L., Beecher G., Dwyer J.T., Folts J., Harnly J., Hollman P., Keen C.L., Mazza G., Messina M., Scalbert A., Vita J., Williamson G., Burrowes J. Flavonoids and heart health. J Nutr 2007, 137(3 Suppl. 1):718S-737S.
24. Etti, K., 1877. Ueber Catechin, Justus Liebig Annalen der Chemie.
25. FDA, 1999. Significant scientific agreement in the review of health claims for conventional foods and dietary supplements. Available from: http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/FoodLabelingNutrition/ucm073332.htm.
26. Feigl E.O. Coronary physiology. Physiol Rev 1983, 63(1):1-205.
27. Felter, H.W., Lloyd, J.U., 1854. King's American Dispensatory.
28. Fisher N.D., Hughes M., Gerhard-Herman M., Hollenberg N.K. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens 2003, 21(12):2281-2286.
29. Flammer A.J., Hermann F., Sudano I., Spieker L., Hermann M., Cooper K.A., Serafini M., Luscher T.F., Ruschitzka F., Noll G., Corti R. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation 2007, 116(21):2376-2382.
30. Francis S.T., Head K., Morris P.G., Macdonald I.A. The effect of flavanol-rich cocoa on the fMRI response to a cognitive task in healthy young people. J Cardiovasc Pharmacol 2006, 47(Suppl. 2):S215-S220.
31. Galleano M., Oteiza P.I., Fraga C.G. Cocoa, chocolate, and cardiovascular disease. J Cardiovasc Pharmacol 2009, 54(6):483-490.
32. Gobburu J.V. Biomarkers in clinical drug development. Clin Pharmacol Ther 2009, 86(1):26-27.
33. Gotti R., Furlanetto S., Pinzauti S., Cavrini V. Analysis of catechins in Theobroma cacao beans by cyclodextrin-modified micellar electrokinetic chromatography. J Chromatogr A 2006, 1112(1-2):345-352.
34. Grassi D., Necozione S., Lippi C., Croce G., Valeri L., Pasqualetti P., Desideri G., Blumberg J.B., Ferri C. Cocoa reduces blood pressure and insulin resistance and improves endothelium-dependent vasodilation in hypertensives. Hypertension 2005, 46(2):398-405.
35. Biomarker Definitions Working Group, 2001. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3), 89-95.
36. Hagendorn E. Tractatus Physico-medicus de Catechu, sive Terra Japonica 1679, British Library, London.
37. Haslam E. Practical polyphenolics: from structure to molecular recognition and physiological action 1998, Cambridge University Press, Cambridge, UK, New York, NY.
38. Hathcock J.N., Shao A. Expanded approach to tolerable upper intake guidelines for nutrients and bioactive substances. J Nutr 2008, 138(10):1992S-1995S.
39. Heiss C., Dejam A., Kleinbongard P., Schewe T., Sies H., Kelm M. Vascular effects of cocoa rich in flavan-3-ols. JAMA 2003, 290(8):1030-1031.
40. Heiss C., Finis D., Kleinbongard P., Hoffmann A., Rassaf T., Kelm M., Sies H. Sustained increase in flow-mediated dilation after daily intake of high-flavanol cocoa drink over 1 week. J Cardiovasc Pharmacol 2007, 49(2):74-80.
41. Heiss C., Jahn S., Taylor M., Real W.M., Angeli F.S., Wong M.L., Amabile N., Prasad M., Rassaf T., Ottaviani J.I., Mihardja S., Keen C.L., Springer M.L., Boyle A., Grossman W., Glantz S.A., Schroeter H., Yeghiazarians Y. Improvement of endothelial function with dietary flavanols is associated with mobilization of circulating angiogenic cells in patients with coronary artery disease. J Am Coll Cardiol 2010, 56(3):218-224.
42. Heiss, C., Keen, C.L., Kelm, M., 2010b. Flavanols and cardiovascular disease prevention. Eur Heart J, [Epub ahead of print].
43. Heiss C., Kleinbongard P., Dejam A., Perre S., Schroeter H., Sies H., Kelm M. Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers. J Am Coll Cardiol 2005, 46(7):1276-1283.
44. Hill A.B. The environment and disease: association or causation?. Proc R Soc Med 1965, 58:295-300.
45. Holt R.R., Lazarus S.A., Sullards M.C., Zhu Q.Y., Schramm D.D., Hammerstone J.F., Fraga C.G., Schmitz H.H., Keen C.L. Procyanidin dimer B2 [epicatechin-(4beta-8)-epicatechin] in human plasma after the consumption of a flavanol-rich cocoa. Am J Clin Nutr 2002, 76(4):798-804.
46. Holt R.R., Schramm D.D., Keen C.L., Lazarus S.A., Schmitz H.H. Chocolate consumption and platelet function. JAMA 2002, 287(17):2212-2213.
47. IOM, 2001. Consensus Report: Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc, 246-9. Available from: http://www.iom.edu/Reports/2001/Dietary-Reference-Intakes-for-Vitamin-A-Vitamin-K-Arsenic-Boron-Chromium-Copper-Iodine-Iron-Manganese-Molybdenum-Nickel-Silicon-Vanadium-and-Zinc.aspx.
48. IOM, 2010. Consensus report: evaluation of biomarkers and surrogate endpoints in chronic disease. Available from: http://www.iom.edu/Reports/2010/Evaluation-of-Biomarkers-and-Surrogate-Endpoints-in-Chronic-Disease.aspx.
49. Kelm M., Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res 1990, 66(6):1561-1575.
50. Kodama S., Yamamoto A., Matsunaga A., Yanai H. Direct enantioseparation of catechin and epicatechin in tea drinks by 6-O-alpha-D-glucosyl-beta-cyclodextrin-modified micellar electrokinetic chromatography. Electrophoresis 2004, 25(16):2892-2898.
51. Kuhnle G., Spencer J.P., Schroeter H., Shenoy B., Debnam E.S., Srai S.K., Rice-Evans C., Hahn U. Epicatechin and catechin are O-methylated and glucuronidated in the small intestine. Biochem Biophys Res Commun 2000, 277(2):507-512.
52. Lanoue L., Green K.K., Kwik-Uribe C., Keen C.L. Dietary factors and the risk for acute infant leukemia: evaluating the effects of cocoa-derived flavanols on DNA topoisomerase activity. Exp Biol Med (Maywood) 2010, 235(1):77-89.
53. Lathia C.D., Amakye D., Dai W., Girman C., Madani S., Mayne J., MacCarthy P., Pertel P., Seman L., Stoch A., Tarantino P., Webster C., Williams S., Wagner J.A. The value, qualification, and regulatory use of surrogate end points in drug development. Clin Pharmacol Ther 2009, 86(1):32-43.
54. Lichtenstein A.H., Appel L.J., Brands M., Carnethon M., Daniels S., Franch H.A., Franklin B., Kris-Etherton P., Harris W.S., Howard B., Karanja N., Lefevre M., Rudel L., Sacks F., Van Horn L., Winston M., Wylie-Rosett J. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006, 114(1):82-96.
55. Loke W.M., Hodgson J.M., Proudfoot J.M., McKinley A.J., Puddey I.B., Croft K.D. Pure dietary flavonoids quercetin and (-)-epicatechin augment nitric oxide products and reduce endothelin-1 acutely in healthy men. Am J Clin Nutr 2008, 88(4):1018-1025.
56. Manach C., Williamson G., Morand C., Scalbert A., Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005, 81(1 Suppl.):230S-242S.
57. Mink P.J., Scrafford C.G., Barraj L.M., Harnack L., Hong C.P., Nettleton J.A., Jacobs D.R. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr 2007, 85(3):895-909.
58. Monagas M., Khan N., Andres-Lacueva C., Casas R., Urpi-Sarda M., Llorach R., Lamuela-Raventos R.M., Estruch R. Effect of cocoa powder on the modulation of inflammatory biomarkers in patients at high risk of cardiovascular disease. Am J Clin Nutr 2009, 90(5):1144-1150.
59. Mullen W., Borges G., Donovan J.L., Edwards C.A., Serafini M., Lean M.E., Crozier A. Milk decreases urinary excretion but not plasma pharmacokinetics of cocoa flavan-3-ol metabolites in humans. Am J Clin Nutr 2009, 89(6):1784-1791.
60. Natsume M., Osakabe N., Oyama M., Sasaki M., Baba S., Nakamura Y., Osawa T., Terao J. Structures of (-)-epicatechin glucuronide identified from plasma and urine after oral ingestion of (-)-epicatechin: differences between human and rat. Free Radic Biol Med 2003, 34(7):840-849.
61. Neveu, V., Perez-Jiménez, J., Vos, F., Crespy, V., du Chaffaut, L., Mennen, L., Knox, C., Eisner, R., Cruz, J., Wishart, D., Scalbert, A., 2010. Phenol-explorer: an online comprehensive database on polyphenol contents in foods. Database, doi: 10.1093/database/bap024 (version 1.5.2). Available at:). http://www.phenol-explorer.eu.
62. Perkins Y. In T.H Tanner: The Practice of Medicine 1869, Renshaw, London.
63. Piskula M.K., Terao J. Accumulation of (-)-epicatechin metabolites in rat plasma after oral administration and distribution of conjugation enzymes in rat tissues. J Nutr 1998, 128(7):1172-1178.
64. Pryseley A., Tilahun A., Alonso A., Molenberghs G. Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints. Clin Trials 2007, 4(6):587-597.
65. Ranade V.V., Somberg J.C. Chiral cardiovascular drugs: an overview. Am J Ther 2005, 12(5):439-459.
66. Ritter C., Zimmermann B.F., Galensa R. Chiral separation of (+)/(-)-catechin from sulfated and glucuronidated metabolites in human plasma after cocoa consumption. Anal Bioanal Chem 2010, 397(2):723-730.
67. Sano A., Yamakoshi J., Tokutake S., Tobe K., Kubota Y., Kikuchi M. Procyanidin B1 is detected in human serum after intake of proanthocyanidin-rich grape seed extract. Biosci Biotechnol Biochem 2003, 67(5):1140-1143.
68. Schroeter H., Heiss C., Balzer J., Kleinbongard P., Keen C.L., Hollenberg N.K., Sies H., Kwik-Uribe C., Schmitz H.H., Kelm M. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. Proc Natl Acad Sci USA 2006, 103(4):1024-1029.
69. Sorond F.A., Lipsitz L.A., Hollenberg N.K., Fisher N.D. Cerebral blood flow response to flavanol-rich cocoa in healthy elderly humans. Neuropsychiatr Dis Treat 2008, 4(2):433-440.
70. Spector L.G., Xie Y., Robison L.L., Heerema N.A., Hilden J.M., Lange B., Felix C.A., Davies S.M., Slavin J., Potter J.D., Blair C.K., Reaman G.H., Ross J.A. Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group. Cancer Epidemiol Biomarkers Prev 2005, 14(3):651-655.
71. Spilker B. Surrogate Endpoints and Biomarkers. Guide to Drug Development: A Comprehensive Review and Assessment 2009, Lippincott, Williams, and Wilkins, Philadelphia, PA, USA.
72. Stalmach A., Mullen W., Steiling H., Williamson G., Lean M.E., Crozier A. Absorption, metabolism, and excretion of green tea flavan-3-ols in humans with an ileostomy. Mol Nutr Food Res 2010, 54(3):323-334.
73. Strick R., Strissel P.L., Borgers S., Smith S.L., Rowley J.D. Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia. Proc Natl Acad Sci USA 2000, 97(9):4790-4795.
74. Taubert D., Berkels R., Roesen R., Klaus W. Chocolate and blood pressure in elderly individuals with isolated systolic hypertension. JAMA 2003, 290(8):1029-1030.
75. Taubert D., Roesen R., Lehmann C., Jung N., Schomig E. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: a randomized controlled trial. JAMA 2007, 298(1):49-60.
76. Thygesen L.C., Andersen G.S., Andersen H. A philosophical analysis of the Hill criteria. J Epidemiol Community Health 2005, 59(6):512-516.
77. USDA, 2003. USDA database for the flavonoid content of selected foods. Available from: http://www.nal.usda.gov/fnic/foodcomp/Data/Flav/flav.html.
78. USDA, 2004. USDA database for the proanthocyanidin content of selected foods. Available from: http://www.nal.usda.gov/fnic/foodcomp/Data/PA/PA.html.
79. USDA, USDHHS, 2005. Dietary Guidelines for Americans. Available from: http://www.health.gov/dietaryguidelines.
80. Wagner J.A. Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol 2008, 48:631-651.
81. Wertmueller C.H. Dissertatio bo tanico medica de Catechu 1779, British Library, London.
82. WHO, 2001. Biomarkers in risk assessment: Validity and Validation. Available from: http://www.inchem.org/documents/ehc/ehc/ehc222.htm.
83. Williamson G., Holst B. Dietary reference intake (DRI) value for dietary polyphenols: are we heading in the right direction?. Br J Nutr 2008, 99(Suppl. 3):S55-S58.
84. Williamson G., Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am J Clin Nutr 2005, 81(1 Suppl.):243S-255S.